Why the study?
Does nicardipine reduce anginal frequency and nitroglycerin consumption in patients with vasospastic angina?
Does nicardipine reduce anginal frequency and nitroglycerin consumption in patients with vasospastic angina?
Nicardipine is effective and safe for the prevention of vasospastic angina.
Answers are grounded in this paper and cite their sources.
Supports nicardipine for vasospastic angina prevention; reinforces placebo-controlled RCT evidence for symptom management.
Anti-ischaemic effects and safety of nicardipine were assessed in 14 patients with vasospastic angina using a placebo comparison, cross-over design study for 8-13 weeks. The average daily dose of nicardipine for optimal angina prevention was 84 mg (range 40-160 mg). Nicardipine administration, as compared with placebo, significantly reduced anginal frequency and nitroglycerin consumption during the single- and double-blind phases of the study. Nicardipine appears to be effective in the prevention of vasospastic angina and not to cause major adverse effects.
No takes yet. Share an insight, caveat, or question.
Pepine et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: